Top-line data demonstrated that the median OS in the intent-to-treat population was 7.5 months (95% CI, 6.5-8.3) with eryaspase and chemotherapy vs 6.7 months (95% CI, 5.4-7.5) with chemotherapy alone (HR, 0.92; 95% CI, 0.76-1.11; P = .375). Read more. . .
Although the addition of eryaspase to chemotherapy improved overall survival (OS) over chemotherapy alone in patients with metastatic pancreatic cancer, the difference in benefit was not found to be statistically significant, missing the primary end point of the phase 3 TRYbeCA-1 trial (NCT03665441).